ArrowArtboardCreated with Sketch.Title ChevronCrossEye IconFacebook IconIcon FacebookGoogle Plus IconLayer 1InstagramCreated with Sketch.Linkedin IconIcon LinkedinShapeCreated with Sketch.Icon Mail ContactPath LayerIcon MailMenu BurgerIcon Opinion QuotePositive ArrowIcon PrintRSS IconIcon SearchSite TitleTitle ChevronTwitter IconIcon TwitterYoutube Icon
Health Technology

Sun Pharmaceutical Industries Ltd.

  • 514.00 INR
  • +5.20
  • +1.02%
  • India
    Apr 19, 2018
  • Ticker
    BOM(524715)
  • Prev. close
    508.80
  • Market cap (INR)
    1,220.74B
  • Market cap (USD)
    18,567.17M
  • Shares
    2,399.26M

Business Summary

Sun Pharmaceutical Industries Ltd. engages in manufacturing, developing, and marketing of pharmaceuticals products. It operates through the following geographical segments: India, the United States of America, Emerging Markets, and Rest of the World. It offers tablets, capsules, injectables, inhalers, ointments, creams, and liquids. The company was founded by Dilip Shantilal Shanghvi in 1982 and is headquartered in Mumbai, India.

Financial Highlights

Mar 2017 INRUSD
Revenue313,081.40M4,668.88M
Gross Profit158,651.20M2,365.91M
Operating income84,884.50M1,265.85M
Income before tax90,478.70M1,349.27M
Net income69,643.70M1,038.57M
EBITDA97,532M1,454.46M
Diluted EPS290.43
Dividends Per Share3.500.05
Total Assets619,117.90M9,534.42M
Total liabilities214,674.70M3,305.99M
Total equity366,396.70M5,642.51M
Operating cash flow71,269.50M1,062.81M
Currency in INRCurrency in USD

Historical Data

 Mar 2013Mar 2014Mar 2015Mar 2016Mar 2017
Revenue 112,388.90M 160,043.90M 272,865M 281,086.10M 313,081.40M
Gross Profit 69,196.20M 102,872.40M 140,261.50M 149,951.40M 158,651.20M
Operating income 45,784.20M 69,559.90M 68,831.20M 75,140.60M 84,884.50M
Income before tax 43,214.40M 45,830.90M 64,029M 65,706.30M 90,478.70M
Net income 29,895.90M 31,433.90M 45,393.80M 45,457.10M 69,643.70M
EBITDA 49,145.90M 73,652.20M 80,778.40M 85,515.90M 97,532M
Diluted EPS 14.40 15.20 18.90 18.90 29
Dividends Per Share 2.50 1.50 3 1 3.50
Total Assets 208,912.80M 293,841M 494,235.80M 559,415.90M 619,117.90M
Total liabilities 42,664.70M 89,379.70M 209,343M 188,572.10M 214,674.70M
Total equity 149,897.30M 185,249.50M 256,231.90M 329,824.80M 366,396.70M
Operating cash flow 35,071.60M 41,341.80M 53,591.20M 67,726.30M 71,269.50M
 Mar 2013Mar 2014Mar 2015Mar 2016Mar 2017
Revenue 2,065.00M 2,648.23M 4,462.70M 4,293.30M 4,668.88M
Gross Profit 1,271.39M 1,702.22M 2,293.97M 2,290.35M 2,365.91M
Operating income 841.22M 1,151.00M 1,125.73M 1,147.69M 1,265.85M
Income before tax 794.01M 758.35M 1,047.19M 1,003.59M 1,349.27M
Net income 549.29M 520.13M 742.41M 694.31M 1,038.57M
EBITDA 902.99M 1,218.71M 1,321.12M 1,306.16M 1,454.46M
Diluted EPS 0.26 0.25 0.30 0.28 0.43
Dividends Per Share 0.04 0.02 0.04 0.01 0.05
Total Assets 3,843.84M 4,920.10M 7,897.50M 8,447.51M 9,534.42M
Total liabilities 784.99M 1,496.58M 3,345.13M 2,847.55M 3,305.99M
Total equity 2,758.00M 3,101.83M 4,094.38M 4,980.55M 5,642.51M
Operating cash flow 644.39M 684.07M 876.48M 1,034.44M 1,062.81M

Valuation Measures

Mar 2017
PER23.71
ROA11.81%
ROE20.00%
Operating margin27.11%
Profit margin22.24%

Key executives

  • Managing Director & Executive Director: Dilip Shantilal Shanghvi
  • Chief Financial Officer: C. S. Muralidharan
  • Compliance Officer, General Manager-Secretarial: Ashok I. Bhuta
  • Vice President & Global Head-Regulatory: Rajeev S. Mathur
  • Senior Vice President-Business Development: Kirti Wardhaman Ganorkar

Shareholders

  • SHANGHVI DILIP SHANTILAL (9.5%)
  • Viditi Investments Pvt Ltd. (8.3%)
  • Tejaskiran Pharmachem Industries Pvt Ltd. (8.1%)
  • Family Investment Pvt Ltd. (7.6%)
  • Quality Synthetic Industries Ltd. (7.6%)
  • Life Insurance Corp. of India (5.5%)
  • Virtuous Finance Ltd. (4.0%)
  • Virtuous Share Investments Pvt Ltd. (3.4%)
  • ICICI Prudential Asset Management Co. Ltd. (3.1%)
  • Aditya Medisales Ltd. (1.6%)

Contact Details

  • Website:http://www.sunpharma.com
  • Address: CTS No. 201 B/1, Sun House, Western Express Highway, Mumbai, 400063, India
  • Phone: +91.22.43244324

Related Companies

  • Sun Pharmaceuticals Morocco LLC Sarlau
  • Sun Pharmaceutical Industries (Australia) Pty Ltd.
  • Ocular Technologies SARL
  • Sun Pharmaceutical Industries Ltd. /7 Brands/
  • Sun Pharmaceutical Industries Ltd. /Bryan Ops/
  • GlaxoSmithKline Plc /Opiates Business/
  • Sun Global Canada Pty Ltd.
  • Sun Pharmaceutical Industries Europe BV
  • Aditya Acquisition Co. Ltd.
  • SPIL de Mexico SA de CV
  • Sun Pharma de Mexico SA de CV
  • Tamil Nadu Dadha Pharmaceuticals Ltd.
  • Pradeep Drug Co. Ltd.
  • Ranbaxy
  • Pharmalucence, Inc.
  • Alkaloida Chemical Co. Exclusive Group Ltd.
  • Sun Pharmaceutical Industries Key Employees Benefit Trust
  • Sun Pharmaceutical Industries, Inc.
  • Chattem Chemicals, Inc.
  • Generic Pharmaceutical Co.
  • Zenotech Laboratories Limited
  • Biosintez OAO
  • MJ Pharmaceuticals Ltd. /Manufacturing Business/
  • Phlox Pharmaceuticals Ltd.
  • Hindustan Antibiotics Ltd.
  • Gujarat Lyka Organics Ltd
  • ICN Magyarorszag Rt
  • Caraco Acquisition Corp.
  • Taro Pharmaceutical Industries Ltd.
  • Caraco Pharmaceutical Laboratories Ltd.

Competitors

  • Dr. Reddy's Laboratories Ltd.
  • Unichem Laboratories Limited
  • Perrigo Co. Plc
  • GlaxoSmithKline Pharmaceuticals Limited
  • Zentiva SA
  • Lupin Limited
  • Dermira Inc
  • Kala Pharmaceuticals, Inc.
  • Nicox SA
  • Cytori Therapeutics, Inc.
  • Antares Pharma, Inc.
  • Hikma Pharmaceuticals Plc
  • Antibiotice SA
  • ANI Pharmaceuticals, Inc.
  • Biofrontera AG
  • Sienna Biopharmaceuticals, Inc.
  • Cumberland Pharmaceuticals Inc.
  • Lannett Company, Inc.
  • Impax Laboratories, Inc.
  • Chunghwa Chemical Synthesis & Biotech Co., Ltd. Class A
  • Curis, Inc.
  • TPI Enterprises Ltd.
  • Acura Pharmaceuticals, Inc.
  • Cytokinetics, Incorporated
  • Evolus, Inc.
  • Intec Pharma Ltd
  • Sol-Gel Technologies Ltd.
Last Updated on 19 Apr, 2018

You have {{numberReadArticles}} FREE ARTICLE{{numberReadArticles-plural}} left this month

Subscribe to get unlimited access to all articles.

Get unlimited access
NAR site on phone, device, tablet

You have {{numberReadArticles}} FREE ARTICLE{{numberReadArticles-plural}} left this month

Subscribe to get unlimited access to all articles.

3 months for $9

Get unlimited access
NAR site on phone, device, tablet

Your trial period has expired

You need a subscription to...

  • Read all stories with unlimited access
  • Use our mobile and tablet apps
See all offers and subscribe

Your full access to the Nikkei Asian Review has expired

You need a subscription to:

  • Read all stories with unlimited access
  • Use our mobile and tablet apps
See all offers
NAR on print phone, device, and tablet media